Riskpilot← Back to searchSign inGet full accessVenomAid Diagnostics ApS
APSActiveCVR 39981165Søltofts Plads 224, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20184 employeeswww.venomaid.com
Revenue 2024
DKK -603K
-492% vs 2023
EBITDA margin
524.0%
-17% vs 2023
Equity ratio
-98.1%
Financial strength
Net profit 2024
DKK -3,7M
-26% vs 2023
| Revenue | DKK -603K | -492% |
| EBITDA | DKK -3,2M | -17% |
| Net profit | DKK -3,7M | -26% |
| Total assets | DKK 7,6M | -27% |
| Equity | DKK -7,4M | -99% |
| Employees | 4 | — |
Legal name
VenomAid Diagnostics ApS
CVR number
39981165
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29. oktober 2018
Share capital
DKK 50.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og bestyrelsesformanden, af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udøve virksomhed med udvikling og salg af diagnostiske produkter til forgiftning forårsaget af dyr samt aktiviteter, som efter ledelsens skøn har tilknytning hertil.
Address
Søltofts Plads 224, 1.
Website
www.venomaid.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 110 | 55 | 90 | 304 | 154 | -603 |
| Staff expenses | -0 | -0 | -32 | -845 | -1.826 | -2.558 |
| EBITDA | 63 | 25 | -24 | -943 | -2.692 | -3.162 |
| Depreciation & amort. | -0 | -0 | -0 | -15 | -61 | -61 |
| EBIT | 63 | 25 | -24 | -958 | -2.753 | -3.223 |
| Net financials | 0 | 0 | -0 | -238 | -783 | -1.214 |
| Profit before tax | 63 | 25 | -24 | -1.196 | -3.536 | -4.437 |
| Tax | 14 | 6 | -0 | -281 | -615 | -743 |
| Net profit | 49 | 20 | -24 | -915 | -2.921 | -3.694 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 113 | 135 | 95 | 6.700 | 10.332 | 7.578 |
| Equity | 99 | 118 | 94 | -821 | -3.742 | -7.436 |
| Long-term debt | 0 | 0 | 0 | 7.337 | 13.315 | 14.646 |
| Short-term debt | 14 | 17 | 1 | 184 | 759 | 368 |
| Total debt | 14 | 17 | 1 | 7.520 | 14.074 | 15.014 |
EBITDA margin
-316163200.0%
This company
15.8%
Market median
-2001033011% vs market
20192024
Equity ratio
-98.1%
This company
38.2%
Market median
-357% vs market
20192024
Return on equity
-369427000.0%
This company
18.4%
Market median
-2007755535% vs market
20192024
Net profit margin
-369427000.0%
This company
8.1%
Market median
-4560827260% vs market
20192024
Asset turnover
-0.08×
This company
1.12×
Market median
-107% vs market
20192024
Debt / equity
2.02×
This company
0.62×
Market median
-226% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-10-29 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RA Management | Management | 2018 | — | — |
JA Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Moleculo Holdings ApS | Company | 33.3% | 33.3% | 2025 |
LAUSTSEN VENTURES ApS | Company | 20.0% | 20.0% | 2025 |
Sirius Ventures ApS | Company | 10.0% | 10.0% | 2025 |
Ubia Holdings ApS | Company | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LAUSTSEN VENTURES ApS
VenomAid Diagnostics ApS Board members of VenomAid Diagnostics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rasmus Aasbjerg Friis | Management | 0 companies |
| Jonas Arnold Jürgensen-Breum | Management | 0 companies |
| Mads Aage Laustsen | Board of Directors | 0 companies |
| Gert Fisker Tomczyk | Chairman | 0 companies |
| Morten Boje Munk | Board of Directors | 0 companies |
| Andreas Hougaard Laustsen-Kiel | Board of Directors | 0 companies |